Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | CDC25C | P30307 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28976337 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| Water SCHEMBL3111611 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| Water SCHEMBL941226 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| SCHEMBL64752 | 0.97 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| Zinc Ion SCHEMBL1863861 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| SCHEMBL6711632 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| SCHEMBL3155238 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| SCHEMBL1022294 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| Silver SCHEMBL10840126 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 | |
| Lithium Ion SCHEMBL411846 | 0.92 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9ACHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714925-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714927-A1 | A REACTIVE RESIN COMPOSITION COMPRISING A PEROXIDE-FREE INITIATOR SYSTEM WITH A SULFINATE AND A TERTIARY AMINE | Hilti Aktiengesellschaft (LI) | 2026-03-25 | — | — | EP | disclosed |
| US-20250270152-A1 | PROCESS FOR PREPARING beta-FARNESENES AND 2-(3-ALKENYL)-1,3-BUTADIENE COMPOUND HAVING RELATED STRUCTURE, AND SYNTHETIC INTERMEDIATE COMPOUND THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-20250230109-A1 | PROCESS FOR PREPARING alpha-FARNESENES AND 4-SUBSTITUTED 3-METHYL-1,3-BUTADIENE COMPOUND HAVING RELATED STRUCTURE, AND SYNTHETIC INTERMEDIATE COMPOUND THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-07-17 | — | — | US | disclosed |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-06-12 | — | — | US | disclosed |
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-02-11 | — | — | US | disclosed |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2023-12-05 | — | — | US | disclosed |
| CN-110234631-B | Composition for treating hypertension and/or fibrosis | 维克特斯生物系统有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3758706-A2 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | The Regents Of The University Of Colorado (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-12-31 | — | — | US | disclosed |
| EP-1199303-A1 | Process for producing retinol and intermediate compounds for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-24 | — | — | EP | disclosed |
| US-6288138-B1 | Dental adhesive kit | SUN MEDICAL CO., LTD. (JP) | 2001-09-11 | — | — | US | disclosed |
| EP-0923924-A2 | Dental adhesive kit | SUN MEDICAL CO., LTD. (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5621084-A | Process for removal of allyl group or allyloxycarbonyl group | PFIZER INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-H1516-H | SUPPORT WITH COLLOIDAL LAYERS AND SILVER HALIDE EMULSIONS | FUJI PHOTO FILM CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0676236-A1 | Process for removal of allyl group or allyloxycarbonyl group | PFIZER INC. (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5424178-A | Grains having a specific aspect ratio on support; backing having a specific smoothness; pictures of a cathode ray tube display; medical diagnosis; x-rays; fluorescence; high speed automatic development; sharp images | FUJI PHOTO FILM CO., LTD. (JP) | 1995-06-13 | — | — | US | disclosed |
| US-5420275-A | Chemiluminescent assay, tumors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0491477-A1 | Pyridopyridazine compounds and their use | Takeda Chemical Industries, Ltd. (JP) | 1992-06-24 | — | — | EP | disclosed |
| US-4349454-A | ENCAPSULATION OF A HYDROPHOBIC-SOLVENT SOLUTION OF A DIAMINODIARYL METHANE SULFONE DERIVATIVE | KANZAKI PAPER MANUFACTURING COMPANY LIMITED (JP) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230109-A1 | PROCESS FOR PREPARING alpha-FARNESENES AND 4-SUBSTITUTED 3-METHYL-1,3-BUTADIENE COMPOUND HAVING RELATED STRUCTURE, AND SYNTHETIC INTERMEDIATE COMPOUND THEREOF | HSD3B1, HSD3B2, HSD11B1 | ACHE 4366/4885ALDH1A1 548/4885CYP3A4 85/4885 |
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | ACHE 4730/4885ALDH1A1 3933/4885CYP3A4 3919/4885 |
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | WEE1, WEE2, NME1 | ACHE 4730/4885ALDH1A1 3933/4885CYP3A4 3919/4885 |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | ACHE 4730/4885ALDH1A1 3933/4885CYP3A4 3919/4885 |
| US-11834417-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | ACHE 2711/4885ALDH1A1 1172/4885CYP3A4 4276/4885 |
| US-20250270152-A1 | PROCESS FOR PREPARING beta-FARNESENES AND 2-(3-ALKENYL)-1,3-BUTADIENE COMPOUND HAVING RELATED STRUCTURE, AND SYNTHETIC INTERMEDIATE COMPOUND THEREOF | GGPS1, HSD3B1, HSD3B2 | ACHE 4534/4885ALDH1A1 1137/4885CYP3A4 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.